# A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

> **NCT04147234** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 42 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BI 1387446 50 μg
- **DRUG:** BI 754091
- **DRUG:** BI 1387446 100 μg
- **DRUG:** BI 1387446 200 μg
- **DRUG:** BI 1387446 400 μg

## Key facts

- **NCT ID:** NCT04147234
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-03
- **Primary completion:** 2022-11-15
- **Final completion:** 2024-03-21
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04147234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04147234, "A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04147234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*